News
CTXR
0.7141
-0.34%
-0.0024
Weekly Report: what happened at CTXR last week (0415-0419)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 43.8% to $4.66 during Thursday's pre-market session. 23andMe Holding stock moved upwards by 26.61% in the pre- market session. NRX Pharmaceuticals shares declined by 22.5% during the session.
Benzinga · 04/18 12:09
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning. Tian Ruixiang stock is rocketing 151% after announcing plans for an extraordinary general shareholders meeting. MicroCloud Hologram shares are soaring over 52% with heavy pre-market trading. Moving stocks this morning are earnings reports, shareholder meetings, public offerings and more.
Investorplace · 04/18 11:27
Weekly Report: what happened at CTXR last week (0408-0412)?
Weekly Report · 04/15 11:48
University Of Minnesota Masonic Cancer Center Intends To Expand Cirtrus Pharmaceuticals' Ongoing Investigator-Initiated Phase 1 Trial Of LYMPHIR In Combination With FDA-Approved CAR-T Products For B-cell Lymphomas
Benzinga · 04/11 12:40
CITIUS PHARMACEUTICALS ANNOUNCES ADDITION OF CITY OF HOPE TO UMN'S PHASE 1 TRIAL OF LYMPHIR IN COMBINATION WITH CAR-T FOR THE TREATMENT OF B-CELL LYMPHOMA
Reuters · 04/11 12:30
Weekly Report: what happened at CTXR last week (0401-0405)?
Weekly Report · 04/08 11:54
Weekly Report: what happened at CTXR last week (0325-0329)?
Weekly Report · 04/01 11:51
Weekly Report: what happened at CTXR last week (0318-0322)?
Weekly Report · 03/25 11:54
Positive Outlook for Citius Pharmaceuticals with Lymphir’s FDA Resubmission and Market Potential
TipRanks · 03/20 17:25
Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment
Healthcare Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment. LYMPHIR is an IL-2-based immunotherapy for the treatment of patients with relapsed or refractory T-cell lymphoma. The FDA has assigned a PDUFA goal date of August 13, 2024.
Seeking Alpha · 03/18 13:26
Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR - Quick Facts
NASDAQ · 03/18 13:05
Weekly Report: what happened at CTXR last week (0311-0315)?
Weekly Report · 03/18 11:52
Weekly Report: what happened at CTXR last week (0304-0308)?
Weekly Report · 03/11 11:48
Citius Pharmaceuticals Secures $2.4M Through New Jersey Economic Development Program
Benzinga · 03/07 13:35
Weekly Report: what happened at CTXR last week (0226-0301)?
Weekly Report · 03/04 11:51
Weekly Report: what happened at CTXR last week (0219-0223)?
Weekly Report · 02/26 12:08
Citius Pharmaceuticals files for $250M mixed securities shelf
Healthcare Citius Pharmaceuticals files for $250M mixed securities shelf Feb. 23, 2024 4:38 p.m. Stock Citius pharmaceuticals, Inc. (CTXR) filed a prospectus related to the offer and sell of up to $250m mixed securities.
Seeking Alpha · 02/23 21:38
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 02/23 11:31
Weekly Report: what happened at CTXR last week (0212-0216)?
Weekly Report · 02/19 12:11
More
Webull provides a variety of real-time CTXR stock news. You can receive the latest news about Citius Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTXR
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.